E-mail: Marek.Trneny@uhkt.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- 5-Azacytidine and G-CSF Derepressed Chromatin Structure of PU.1 and Its Targets Cebpa and Cbfb In Myelodysplastic Syndrome (MDS)
- A MULTICENTER, PHASE IV OBSERVATIONAL SAFETY STUDY OF OFATUMUMAB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) STUDY
- A MULTICENTER, RANDOMIZED PHASE III STUDY OF RITUXIMAB AS MAINTENANCE TREATMENT VERSUS OBSERVATION ALONE IN PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA: THE AGMT NHL13 TRIAL
- A RETROSPECTIVE STUDY TO ASSESS RELATIVE DOSE INTENSITIES IN PATIENTS WITH LYMPHOMA IN CENTRAL EUROPEAN COUNTRIES
- Activation of Chromatin Structure Upstream PU.1 Gene and in Vitro Differentiation in High Risk Myelodysplastic Syndrome Following 5-Azacytidine
- Active Chromatin Structure near MYB Occupancy at the Mir-155 Host Gene Promoter Coincides with Increased Mir-155 and MYB Levels In Chronic Lymphocytic Leukemia
- Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma: Data from National Czech Registry.
- ALTERATIONS OF CHEK2 GENE IN NON-HODGKIN LYMPHOMA PATIENTS
- ANALYSIS OF RISK FACTORS OF 248 PATIENTS WITH B-CHRONIC LYMPHOCYTIC LEUKEMIA AT DIAGNOSIS
- AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL).
- AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety of lenalidomide plus rituximab (R2) versus placebo plus rituximab.
- CD10 EXPRESSION IN LYMPH NODE STROMAL CELLS DOES NOT SIGNIFICANTLY INFLUENCE GENE EXPRESSION ANALYSIS OF CD10 POSITIVITY OR NEGATIVITY OF A TUMOR
- CD31/PECAM-1 Is Overexpressed On Mantle-Cell Lymphoma (MCL) Primary Cells and Positively Regulates Engraftment and Growth of MCL Cell Lines in Immunodeficient Mice
- CLINICAL FINDINGS AND TREATMENT OF ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: THE ANALYSIS OF THE 1425 PATIENTS INCLUDED IN CZECH LYMPHOMA PROJECT (CLP)
- CLONAL EVOLUTION STUDIED BY I-FISH IN B-CLL
- Confirmation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) in An Independent Prospective Patient Cohort
- Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab
- DASATINIB EFFICACY AND TOLERANCE IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT/INTOLERANT TO IMATINIB IN THE CONTEXT OF REAL CLINICAL PRACTICE MANAGEMENT
- DASATINIB EVEN AT LOWER DOSES IS AN EFFECTIVE FOR CHRONIC MYELOID LEUKAEMIA TREATMENT IN PATIENTS RESISTANT OR INTOLERANT TO IMATINIB
- DIAGNOSTIC AND THERAPEUTIC APPROACH TO SMALL LYMPHOCYTIC LYMPHOMA (SLL): EXPERIENCE OF CZECH LYMPHOMA STUDY GROUP
- Diagnostika lymfadenopatií průtokovou cytometrií
- Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study
- Difuzní velkobuněčný B lymfom, charakteristika a léčba, data z registru Kooperativní lymfomové skupiny
- Disruption of a Functional Relationship Between PU.1 and Mir-155 during the Pathogenesis of Chronic Lymphocytic Leukemia (CLL)
- DISTINGUISHING OF PRIMARY MEDIASTINAL B-CELL LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA USING REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION
- DISTINGUISHING OF PRIMARY MEDIASTINAL B-CELL LYMPHOMA IN A GROUP OF DIFFUSE LARGE B-CELL LYMPHOMA USING GENE EXPRESSION OF SELECTED GENES
- DMSO Reduction Strategies Reduce DMSO Induced Post Autologous Transplant Morbidity In Patients with Lymphoma and Myeloma –Results from an EBMT Non Interventional Prospective Study
- EFFECTS OF PRETRANSPLANTATION TREATMENT WITH RITUXIMAB ON OUTCOMES OF AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR DIFFUSE LARGE B-CELL LYMPHOMA
- ELDERLY WOMEN WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH RITUXIMAB BASED CHEMOTHERAPY DO NOT HAVE BETTER OUTCOME COMPARED TO MEN
- ENDOTHELIAL CELLS (EC) AND ENDOTHELIAL PRECURSOR CELLS (EPC) KINETICS IN HAEMATOLOGICAL PATIENTS UNDERGOING CHEMOTHERAPY OR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)
- European MCL Network: An Update on Current First Line Trials.
- EXPRESSION OF CD66ABCE ON TUMOR CELLS IN NON-HODGKIN LYMPHOMAS AND MULTIPLE MYELOMA
- Factors Affecting Quality of Life During and After Stem Cell Transplantation in Long Term Survivors – Comparison of Autologous and Allogeneic Stem Cell Transplantation
- Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia
- FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) IN FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RETROSPECTIVE ANALYSIS OF CZECH CLL STUDY GROUP
- Fludarabine, Cyclophosphamide and Rituximab (FCR) Related Prolonged Cytopenia Is Frequent and Adverse Factor Affecting Survival of Patients with Chronic Lymphocytic Leukemia (CLL)
- Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)
- Frontline Intensive Chemotherapy Brings Survival Benefit In Young, Risky Patients With Follicular Lymphoma: Pair-Matched Analysis From The Czech Lymphoma Study Group (CLSG) Database
- GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
- GADOLIN: PRIMARY RESULTS FROM A PHASE III STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE COMPARED WITH BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT NONHODGKIN LYMPHOMA
- Hematopoietic Stem and Progenitor Cells in Patients with Mature B-Cell Malignancies Are Quantitatively and Qualitatively Deregulated Compared to Healthy Controls
- Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG)
- Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)
- IMMUNO CHEMOTHERAPY (ANTI CD20 AND FLUDARABIN/CYCLOPHOSPHAMIDE) AND HIGH DOSE CHEMOTHERAPY WITH ASCT INCREASES MOLECULAR REMISSION RATE BUT CANNOT PREVENT RELAPSES
- Immunomodulatory Agent Lenalidomide Enhances Antitumor Functions of Chimeric Receptor-Modified T Cells in Vitro and in Vivo
- IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR’S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY
- Impact Of Rituximab Maintenance Schedule On Prognosis In First Line Treatment Of Follicular Lymphoma. Retrospective Analysis From Czech Lymphoma Group (CLG) Database
- Impaired Peripheral Blood Dendritic Cell Counts in B-Chronic Lymphocytic Leukaemia
- Improving Survival in Patients with Chronic Lymphocytic Leukemia - Population Based Study
- Independent Predictive Value of PET-CT Pre Transplant in Relapsed and Refractory Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Included in the CORAL Study
- Intensive Induction Is Beneficial for High Risk Younger Patients with Aggressive B-Cell Lymphoma, While Frontline ASCT Brings No Benefit: Final Analysis of MegaCHOP-BEAM and MegaCHOP-ESHAP-BEAM Studies
- INTENSIVE TREATMENT OF HIGH-RISK AGGRESSIVE B-CELL LYMPHOMAS WITH MEGACHOP-ESHAP-BEAM REGIMEN WITH OR WITHOUT RITUXIMAB: RESULTS OF THREE CONSECUTIVE TRIALS OF CLSG
- Intersticiální pneumonie jako projev toxicity kombinované léčby rituximabem, filgrastimem a cyklofosfamidem.
- Kooperativní lymfomová skupina (Czech Lymphoma Study Group)
- Léčba lymfomů CNS
- Léčba periferních T-nehodgkinských lymfomů v České republice
- Lenalidomide Exhibits Activity in Mantle Cell Lymphoma through Increased NK Cell Mediated Cytotoxicity
- LIMITED NUMBER OF GENES DISTINGUISHES BETWEEN GERMINAL CENTRE-LIKE AND NONGERMINAL CENTRE-LIKE DIFFUSE LARGE B CELL LYMPHOMA
- Lymfom z plášťových buněk - od zpřesnění diagnostiky k hledání účinné terapie
- Lymfoproliferativní choroby a solidní nádorová duplicita
- Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis.
- Mantle Cell Lymphoma International Prognostic Score Is Valid and Confirmed in Unselected Cohort of Patients Treated in Rituximab Era
- MCL1 Targeting Agent Homoharringtonine Exerts Strong Cytotoxicity Towards Diffuse Large B-Cell Lymphoma (DLBCL) Cells and Synergizes with BCL2 Targeting Agent ABT199 in Eliminating BCL2-Positive DLBCL Cells
- Median Absolute Lymphocyte Count Independently Predicts Survival of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-Chemotherapy: Analysis of 651 Patients Included In the Czech Lymphoma Project
- MicroRNA Mir-155 and Myb Proto-Oncogene Family Members Cooperate in Pathogenesis of Chronic Lymphocytic Leukemia
- Minimal Residual Resistance In CML: Stable BCR-ABL Gene Expression at Levels 0.01–0.1% (IS) In the Consecutive Samples May Be Associated with BCR-ABL Mutation Development and MMoR Lost In a Small Number of Tyrosine Kinase Inhibitor Responders
- Mouse Models of Human Mantle Cell Lymphoma for the Study of Disease Biology and for Pre-Clinical Assessment of Experimental Treatment Approaches
- NEW PROGNOSTIC MARKERS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE EVERYDAY HEMATOLOGICAL PRACTICE. A MULTICENTER ANALYSIS
- Observational Study Alternating R-CHOP21 and R-Cytarabine (3+3 Cycles) for Patients with Newly Diagnosed Mantle Cell Lymphoma Not Eligible for High-Dose Therapy: A Czech Lymphoma Study Group Trial Preliminary Results
- Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An Internatio
- Oncogenic Micrornas In Cerebrospinal Fluid and Sera Reflect Therapy Efficacy and Their Reappearance Precedes Clinical Relapse In Primary and Secondary CNS Lymphoma
- Outcome and Prognostic Factors in Patients with Mantle Cell Lymphoma Relapsing After Autologous Stem Cell Transplantation: A Retrospective Study of the EBMT
- Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study
- PATTERN OF ANGIOGENESIS-RELATED GENE EXPRESSION DURING IN VIVO GROWTH OF MANTLE CELL LYMPHOMA CELL LINE JEKO-1
- Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study
- Platelet-endothelial cell adhesion molecule (PECAM-1/CD31) is upregulated during growth of mantle cell lymphoma cell line JEKO-1 in immunodeficient mouse
- POSITIVE PRETRANSPLANTATION POSITRON EMISSION TOMOGRAPHY INDICATES POOR PROGNOSIS IN RELAPSED HODGKIN LYMPHOMA PATIENTS
- Postavení, přínos a možná úskalí integrovaného 18FDG PET/CT vyšetření u nemocných s ne-hodgkinskými lymfomy
- Prediction of outcome using positron emission tomography (PET) compared to standard response criteria and potential role in treatment decisions in diffuse large B-cell lymphoma (DLBCL) patients.
- PREDICTIVE VALUE OF EARLY 18FDG POSITRON EMISSION TOMOGRAPHY (PET) IN HIGH-RISK AGGRESSIVE B-LYMPHOMAS TREATED WITH RITUXIMAB, INTENSIVE INDUCTION THERAPY AND AUTOLOGOUS TRANSPLANTATION
- Prevalence and Prognostic Value of BCL2 and MYC Protein Expression within ABC and GCB Subtypes in Patients with Previously Untreated, Diffuse Large B-Cell Lymphoma: Analysis from the Phase III MAIN Study
- Primární lymfomy centrálního nervového systému:data z registru kooperativní lymfové skupiny (KLS)
- Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study
- Principy stagingu a hodnocení léčebné odpovědi u non-hodgkinských lymfomů
- QUALITY OF LIFE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS TREATED WITH LENALIDOMIDE VS INVESTIGATOR’S CHOICE: MCL-002 (SPRINT) TRIAL
- R-CHOP Versus R-FC Followed by Maintenance with Rituximab Versus Interferon-Alfa: Outcome of the First Randomized Trial for Elderly Patients with Mantle Cell Lymphoma
- R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study
- R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. CORAL Study.
- Radiotherapy With Rituximab Is Better than Radiotherapy alone In First Line Treatment Of Localized Follicular Lymphoma. Time To Change a Standard Strategy?
- Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (
- Randomizovaná studie léčby mladých nemocných s nízce rizikovým difúzním velkobuněčným B lymfomem (DLBCL) s nízkým a srovnávající CHOP-like režim s rituximabem nebo bez rituximabu, (Mabthera International Trial, MInT). První analýza kompletní studie.
- Reduced Intensity Allogeneic Stem Cell Transplantation for Follicular Lymphoma Results in An Improved Progression Free Survival When Compared to Autologous Stem Cell Transplantation. An Analysis from the Lymphoma Working Party of the EBMT
- Relapse of Hodgkins lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT
- Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project
- Revalidation of FLIPI in patients with follicular lymphoma (FL) registered in the F2 study and treated upfront with immunochemotherapy.
- RITUXIMAB MAINTENANCE SIGNIFICANTLY PROLONGS DURATION OF REMISSION IN ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA. FIRST RESULTS OF A RANDOMIZED TRIAL OF THE EUROPEAN MCL NETWORK
- Rituximab Maintenance Significantly Prolongs Event Free (EFS) and Progression Free Survival (PFS) In Male Patients With Aggressive B-Cell Lymphoma In The NHL13 Study
- RITUXIMAB SIGNIFICANLY IMPROVES THE OUTCOME OF YOUNG POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA - ON BEHALF OF CZECH LYMPHOMA STUDY GROUP
- Roscovitine Sensitizes Leukemia and Lymphoma Cells to TRAIL-Induced Apoptosis and Enhances Cell-Mediated Cytotoxicity
- SIGNIFICANT SURVIVAL IMPROVEMENT OF THE ELDERLY PATIENTS AND WOMEN WITH LOW/INTERMEDIATE RISK MIPI MANTLE CELL LYMPHOMA OVER THE PERIOD OF 14 YEARS
- Sledování klonálního vývoje u B-CLL metodou I-FISH
- SMALL LYMPHOCYTIC LYMPHOMA (SLL): RETROSPECTIVE ANALYSIS FROM THE REGISTRY OF CZECH LYMPHOMA STUDY GROUP
- SPLENECTOMY IN THE TPO MIMETIC ERA – STILL REASONABLE APPROACH?
- SPONTANEOUS TRANSFORMATION OF LYMPH NODE AND BONE MARROW STROMAL CELLS FROM CANCER PATIENTS
- Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887).
- Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator’s choice in relapsed/refractory mantle cell lymphoma.
- Symptoms and Toxicity of Rituximab Maintenance (R-M) Versus Observation (OBS) Following Rituximab Plus Chemotherapy in Patients with Follicular Lymphoma
- The Addition of Bevacizumab to Standard Therapy with R-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Is Associated with an Increased Rate of Cardiac Adverse Events: Final Analysis of Safety and Efficacy Outcomes From the...
- The Addition of Rituximab Eliminates the Negative Prognostic Impact of PMBCL Compared to DLBCL in Young Patients with CD20-Positive Aggressive Lymphomas Receiving a CHOP-Like Chemotherapy: Results of a Subgroup Analysis of the Mabthera International
- The Gene Expressions of hOCT1 and ABCB1 Change During the Course of CML in Relation to Imatinib Therapy
- THE IMPACT OF THERAPY INTENSIFICATION AND OUTCOME OF 6 CML PATIENTS WITH THE SAME TYPE OF BCR-ABL MUTATION M244V
- THE INCIDENCE OF SECONDARY TUMORS IS NOT HIGHER IN PATIENTS TREATED FOR CLL COMPARED TO THE UNTREATED COHORT OF PATIENTS BUT IT IS HIGHER IN OLDER COMPARED WITH YOUNGER TREATED PATIENTS
- THE OCCURRENCE OF CNS RELAPSES IN HIGH-RISK AGGRESSIVE LYMPHOMA PATIENS TREATED WITH INTENSIFIED INDUCTION AND HIGH-DOSE CONSOLIDATION PROTOCOLS OF THE CZECH LYMPHOMA STUDY GROUP
- The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI)
- The Rituximab Treament for Relapsed Follicular Lymphomas Changes the Duration of Subsequent Responses. the Analysis on Behalf of CLSG
- THE TREATMENT MODIFICATION DOES NOT SEEM TO CHANGE THE DLBCL PATIENT´S OUTCOME WHEN CORRELATED WITH EARLY PET RESULTS
- Treatment of Diffuse Large B-Cell Lymphoma with Rituximab, Intensive Induction and High-Dose Consolidation: The Final Analysis of the Czech Lymphoma Study Group (CLSG) R-MegaCHOP-ESHAP-BEAM (R-MEB) Trial.
- ULTRA-DEEP SEQUENCING WITH COMPUTED THRESHOLDS FOR SENSITIVE MUTATION ANALYSIS IN THE KINASE DOMAIN OF BCR-ABL: FOCUSED ON DEEP MUTATION DETECTION IN CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
- Ultradeep-Amplicon Pyrosequencing for Mutation Detection in the Kinase Domain of BCR-ABL Revealed Artificial Low-Level Variants That Need to Be Avoided for Relevant Mutational Data Interpretation
- VALUE OF 18F-FDG PET/CT FOR THE STAGING OF NON-HODGKIN´S LYMPHOMA: SIGNIFICANT IMPROVEMENT IN THE DETECTION OF NODAL AND EXTRANODAL LESIONS BUT MARGINAL IMPACT ON DISEASE STAGE
- Význam rituximabu v předtransplantační terapii na léčebné výsledky po autologní transplantaci u pacientů s difuzním velkobuněčným lymfomem.
- Základní principy léčby maligních lymfomů
Články v Klinické onkologii
- Difuzní velkobuněčný B lymfom – moderní způsoby diagnostiky a molekulárně cílené léčby
- Distribuce podtypů non-hodgkinského lymfomu v České republice a jejich přežití
- Editorial
- Folikulární lymfom
- Hodgkinův lymfom – vývoj léčebných přístupů a současné trendy
- Hodnocení klinického stadia a léčebné odpovědi u maligních lymfomů – doporučení Kooperativní lymfomové skupiny na základě revidovaných kritérií z roku 2014 (Luganská klasifikace)
- Indikace k alogenním a autologním transplantacím krvetvorných buněk. Doporučení České hematologické společnosti ČLS JEP a České onkologické společnosti ČLS JEP.
- Léčba pacientů s relabovaným/refraktérním Hodgkinovým lymfomem
- Lymfom z plášťových buněk – současný stav poznání a možnosti léčby
- Maligní lymfomy − minulost, současnost a budoucnost
- Muž s dýmkou, prof. MUDr. Pavel Klener, DrSc., se v dubnu 2022 dožívá 85 let
- Podávání interleukinu - 2 v časné fázi po autologní transplantaci krvetvorných buněk u nemocných s maligními lymfomy
- Postavení radioterapie v léčbě maligních lymfomů – doporučení Kooperativní lymfomové skupiny
- Primární testikulární lymfom, klinickopatologická multicentrická retrospektivní studie a data registru Kooperativní lymfomové skupiny (KLS)
- Prof. MUDr. Pavel Klener, DrSc., se v dubnu 2017 dožívá 80 let
- Současné možnosti imunoterapie nádorových onemocnění
- Současné postavení transplantace krvetvorných buněk v léčbě lymfomů – přehled
- Srovnávání účinnosti mobilizačního režimu s cyklofosfamidem + G-CSF a režimu IVE + G- CSF u nemocných s maligními lymfomy
- Určování rozsahu onemocnění u non-Hodgkinových lymfomů – doporučení Kooperativní lymfomové skupiny
- Vyšetření mediastina u nemocných s maligním lymfomem- využití tří zobrazovacícm metod: počítačové tomografie, galliové scintigrafie, magnetické rezonance. První výsledky.
- Význam klinického registru nemocných s lymfomy – přínos, možnosti a limitace
- Význam minimální reziduální nemoci a metody jejího stanovení u pacientů s některými hematologickými malignitami
- Význam selekce CD 34+ progenitorů u nemocných s non-Hodgkinským lymfomem léčených vysokodávkovanou chemoterapií s následnou autologní transplantací krvetvorných buněk
- Záchranná léčba a role transplantací u lymfomů
Stránky na Linkosu
Léčebné postupy
- Diagnostické a léčebné postupy u nemocných s maligními lymfomy. 12. vydání
- Hodnocení klinického stadia a léčebné odpovědi u maligních lymfomů – doporučení Kooperativní lymfomové skupiny na základě revidovaných kritérií z roku 2014 (Luganská klasifikace)
- Minimální doporučená léčebná strategie u difuzního velkobuněčného B-nehodgkinského lymfomu (DLBCL)
- Minimální doporučená léčebná strategie u folikulárního lymfomu (FL)
- Minimální doporučená léčebná strategie u chronické lymfatické leukémie (CLL)
